The A4 and other similar (small) studies strongly support the launch of major trials of left atrial catheter ablation for the maintenance of sinus rhythm, reduction of cardiovascular hospitalizations and improved survival in patients with symptomatic recurrent atrial fibrillation. Will pharmacological therapies continue to have an important place in the management of atrial fibrillation?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cappato, R. et al. Fatalities in catheter ablation of atrial fibrillation. J. Am. Coll. Cardiol. (in press).
Jaïs, P. et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118, 2498–2505 (2008).
Krittayaphong, R. et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J. Med. Assoc. Thai. 86 (Suppl. 1), S8–S16 (2003).
Wazni, O. M. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293, 2634–2640 (2005).
Stabile, G. et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur. Heart J. 27, 216–221 (2006).
Oral, H. et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N. Engl. J. Med. 354, 934–941 (2006).
Pappone, C. et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J. Am. Coll. Cardiol. 48, 2340–2347 (2006).
Forleo, G. B. et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J. Cardiovasc. Electrophysiol. 20, 22–28 (2009).
Hindricks, G. et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 112, 307–313 (2005).
Hohnloser, S. H. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668–678 (2009).
Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119–125 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.J. Camm has declared that he is a consultant for Sanofi Aventis, Cardiome/Astellas and Boston Scientific, and has received speakers bureau from Sanofi Aventis and Cardiome/Astellas. I. Savelieva has declared no competing interests.
Rights and permissions
About this article
Cite this article
Camm, A., Savelieva, I. A4 study: proof of concept?. Nat Rev Cardiol 6, 332–334 (2009). https://doi.org/10.1038/nrcardio.2009.49
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.49
